Importantly, the administration of IPI-504, an inhibitor of HSP90, selectively inhibited the proliferation and metastasis of breast cancer cells with BAG2-induced mutant p53 aggregates under chemotherapeutic regimens. This evidence concerns the gene BAG2 and breast cancer.